ALSO NOTED: Jarvik takes fourth in ad ranking;Glaxo slashes AIDS drug costs for poor;

> Which TV drug ads lodged most securely in consumers' brains? That ubiquitous Nasonex bee hit No. 1, with Rozerem's talking animal coming in second. The Vytorin ads--pulled in the wake of the controversial Enhance trial--took third place, while the also-controversial Lipitor campaign featuring Robert Jarvik came in fourth. Report | Ranking

> Some biotechs are eager for the FDA approval of biogeneric drugs. Report

> A Nevada judge knocked down a $134 million jury award to three women who blamed Wyeth's hormone therapies for their breast cancer; the new figure is about $58 million. The company still faces some 5,000 similar lawsuits across the country. Report

> GlaxoSmithKline cut the cost of its AIDS drugs for patients in the world's poorest countries; one drug often used in children was discounted 40 percent. Report

> Covering the cost of drugs for people who have heart attacks would lengthen lives and lower medical costs, new research shows. Report

> Thailand's plan to review its compulsory licensing of four cancer drugs hit a big obstacle when three government ministers found that it cannot be revoked. Report

> Watson Pharmaceutical posted fourth-quarter profits of $38.4 million, a big swing upward from last year's loss of $489 million on acquisition and R&D charges. Sales grew slightly to $627.3 million. Release | Report

> India's Sun Pharmaceutical increased its stake in Israel-based Taro Pharmaceutical industries to 34.4 percent. Report

> Moody's upped its rating on Merck KGaA to "positive" from "stable," citing the German company's rapid de-leveraging. Report

> IDM Pharma said it had met minimum bid price requirements to regain compliance with Nasdaq Stock Market rules. Report

> A new survey has concluded that specialists feel Medicare's new anemia drug payment limits are hurting cancer patients. Report

> Do the psychiatric symptoms seen in some Chantix patients say more about cigarettes than about the drug? Report

And Finally... Here's a new business model for biotechnology: Pet cloning. South Korea's RNL Bio says it has its first $50,000 order to clone a dog from the biologic material remaining from a California woman's pet bull terrier. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.